BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Relmada Therapeutics Completes $8 Million Capital Raise in Series A Financing


10/1/2013 6:35:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing

NEW YORK
, Oct. 1, 2013 /PRNewswire/ -- Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain,today announced the final closing of a Series A financing raising $8 million in gross proceeds. The offer was oversubscribed and Laidlaw & Company (UK) Ltd. acted as the exclusive placement agent.

The company intends to use the Series A proceeds to continue the development of its product pipeline and for general corporate activities. "This impressive response from investors clearly shows the potential of our diversified product portfolio of drug candidates aimed to address the significant unmet medical need in chronic pain," said Sergio Traversa, CEO of Relmada. Based on this successful offering, we plan to complete the required steps for LevoCap ER to enter Phase III of development, d-methadone to enter Phase IIb, MepiGel and BuCap to start the pilot PK studies and to prepare the company for a public transaction in the first half of 2014.

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatment of pain. Relmada's strategy focuses on two complementary pillars: the improvement of proven drug candidates with novel delivery methods and pharmaceutical compositions and the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor platform.

The Company is currently developing several drug candidates including: LevoCap ER, its abuse resistant, oncea-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for diabetic painful neuropathy (DPN); BuCap, its oral dosage form of the opioid analgesic buprenorphine; MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.

About Laidlaw & Company, LTD.

Laidlaw & Company is a full service investment bank and securities brokerage firm with offices in New York, London, San Francisco and select additional locations. Its corporate finance efforts are focused on the healthcare, natural resource and social commerce sectors. In addition to capital raising, its investment banking arm provides M&A, restructuring and other financial advisory services for public and private small cap and middle market clients across a broad crosssection of industry sectors. Its brokerage arm provides wealth management services for domestic and international highnetworth and institutional clients. Laidlaw is authorized by the FSA in the United Kingdom, and is regulated by FINRA in the United States. (Source: http://www.laidlawltd.com).

Safe Harbor Statement

This release contains forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forwardlooking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. The Company assumes no obligation to update or supplement any forwardlooking statements whether as a result of new information, future events or otherwise.

Visit our website at www.relmada.com

SOURCE Relmada Therapeutics Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES